
TORONTO, Sept. 19 /CNW/ - Patheon Inc. (TSX: PTI) today announced that CEPH International Corporation (CEPH) received late Friday afternoon (Eastern Time) a Warning Letter from the San Juan, Puerto Rico District office of the U.S. Food and Drug Administration, (FDA). CEPH, a subsidiary of MOVA Pharmaceutical Corporation which was acquired by Patheon in December 2004, operates a facility in Carolina, Puerto Rico. The Warning Letter claims that variations in assay, fill-weight, content uniformity and related issues for an oral powder for suspension product manufactured by CEPH indicate a failure by CEPH to comply with current Good Manufacturing Practices (cGMP) of the U.S. Federal Food, Drug and Cosmetic Act. This action resulted from the FDA inspection of CEPH's manufacturing facilities which was completed in April 2005. CEPH is required to respond to the Warning Letter within 15 working days with details of the specific steps CEPH has taken or will take to correct the situation. In response to the FDA's concerns, CEPH has taken several actions, including purchasing new equipment which is currently under validation. Patheon is taking immediate action to address the concerns raised by the FDA and a senior team of Patheon specialists will be working closely with CEPH management and CEPH's client in this regard. Patheon will issue a further news release if material developments occur with respect to this matter. Patheon (TSX:PTI; www.patheon.com) is a leading global provider of drug development and manufacturing services to the international pharmaceutical industry. With the addition of its wholly owned subsidiary MOVA Pharmaceutical Corporation, acquired in December 2004, Patheon operates a network of 14 facilities in the United States, Canada and Europe, employing more than 5,900 people and serving a client base of 180 pharmaceutical and biotechnology companies. %SEDAR: 00001700E